CEO Renée Aguiar-Lucander (Calliditas)
November 9, 2020 06:56 AM ESTUpdated 05:31 PM
R&D

New­ly Nas­daq-list­ed Cal­lid­i­tas surges af­ter lead kid­ney drug hits pri­ma­ry end­point

Jason Mast

Editor

Cal­lid­i­tas still hasn’t proven to pa­tients that their kid­ney drug has long-term ben­e­fits, but the com­pa­ny says they’ve seen more than enough to go to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times